Earnings ·
Veru enrolls 239 patients in Phase 2b PLATEAU trial, secures Novo Nordisk supply deal and USPTO patent allowance
VERUVeru Inc.
Veru Inc. reported fiscal third quarter results ending June 30, 2026, with a net loss of $7.0 million ($0.30 per share), compared to a $7.3 million loss in the prior year period. Research and development expenses rose to $4.4 million from $3.0 million, while general and administrative costs fell to $3.4 million from $5.0 million. The company holds $23.9 million in cash as of June 30, 2026. Clinically, the Phase 2b PLATEAU trial for enobosarm combined with semaglutide fully enrolled 239 patients, exceeding its target of 200. Veru secured a clinical supply agreement with Novo Nordisk and received a USPTO notice of allowance for a key patent covering the combination therapy, extending protection until at least October 2044. Interim analysis results are expected in Q1 2027. Veru Inc. is a late-stage biopharmaceutical company developing treatments for cardiometabolic and inflammatory diseases.